Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Shield Therapeutics Plc
November 2024 Investor Forum
21st Nov 2024
Custodian Property Income REIT plc
November 2024 Investor Forum
20th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
105: Finding the venture opportunity in the energy transition | Reuben Wilcock of Blackfinch Ventures
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
Shield Therapeutics Plc
Life Sciences
November 2024 Investor Forum
By
Dr Martin Hall
21 Nov 2024
Tissue Regenix
Life Sciences
Maiden pre-tax profit
By
Dr Martin Hall
23 Sep 2024
Stay up-to-date with the latest research
Sign up to our newsletter
Shield Therapeutics Plc
Life Sciences
Focusing on successful execution
By
Dr Martin Hall
11 Sep 2024
Life Sciences
Survival of the UK life sciences sector
By
Dr Martin Hall
25 Jun 2024
Shield Therapeutics Plc
Life Sciences
Cash management is key
By
Dr Martin Hall
23 May 2024
Tissue Regenix
Life Sciences
Six consecutive periods of >20% growth
By
Dr Martin Hall
10 Apr 2024
Life Sciences
Hardman & Co Healthcare Index
By
Dr Martin Hall
12 Jan 2024
Shield Therapeutics Plc
Life Sciences
Accelerating effectiveness of enlarged sales team
By
Dr Martin Hall
15 Nov 2023
Tissue Regenix
Life Sciences
Continuation of the positive momentum
By
Dr Martin Hall
18 Sep 2023
Shield Therapeutics Plc
Life Sciences
Accrufer Rx momentum gathering
By
Dr Martin Hall
25 Jul 2023
International Biotechnology Trust
Life Sciences
Industry M&A remains a key driver
By
Dr Martin Hall
10 Jul 2023
1
2
3
...
22
Next
